|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.89 USD | -1.64% |
|
-13.19% | -27.39% |
| 07-24 | Jefferies Cuts Summit Therapeutics Price Target to $15 From $17, Hold Rating Kept | MT |
| 07-24 | Summit Therapeutics Inc., Q2 2026 Earnings Call, Jul 23, 2026 |
Company Valuation: Summit Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 1,436 | 10,512 | 10,021 | 7,857 | - | - |
| Change | - | 631.97% | -4.67% | -21.6% | - | - |
| Enterprise Value (EV) 1 | 1,436 | 10,512 | 9,493 | 7,383 | 7,655 | 7,430 |
| Change | - | 631.97% | -9.69% | -22.22% | 3.67% | -2.94% |
| P/E | -2.62x | -58.1x | -12.2x | -10.9x | -11.6x | -21.4x |
| PBR | - | - | 20.7x | 38.9x | 394x | 24.6x |
| PEG | - | 0.8x | -0x | 0.7x | 2.09x | 0.5x |
| Capitalization / Revenue | - | - | - | 2,594x | 178x | 18x |
| EV / Revenue | - | - | - | 2,437x | 173x | 17.1x |
| EV / EBITDA | - | -96.9x | -11.7x | -12.9x | -14x | -23.8x |
| EV / EBIT | - | -58.8x | -11.7x | -11.2x | -10.9x | -17.1x |
| EV / FCF | - | -93.4x | -39.6x | -13.1x | -14.3x | -15x |
| FCF Yield | - | -1.07% | -2.52% | -7.65% | -6.98% | -6.66% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.7828 | -0.2452 | -1.066 | -0.9024 | -0.8524 | -0.4597 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | - | - | - | 3.029 | 44.26 | 435.3 |
| EBITDA 1 | - | -108.4 | -810.4 | -571.6 | -547 | -311.8 |
| EBIT 1 | - | -178.8 | -810.5 | -657.6 | -701.6 | -435.6 |
| Net income 1 | -486.2 | -175.1 | -799.5 | -698 | -713.3 | -391.6 |
| Net Debt 1 | - | - | -528.6 | -473.6 | -202.3 | -427.3 |
| Reference price 2 | 2.049 | 14.254 | 12.995 | 9.849 | 9.849 | 9.849 |
| Nbr of stocks (in thousands) | 700,843 | 737,448 | 771,150 | 797,750 | - | - |
| Announcement Date | 20/02/24 | 24/02/25 | 23/02/26 | - | - | - |
1GBP in Million2GBP
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -11.3x | 3025.58x | -12.92x | -.--% | 10.45B | |
| 33.11x | 8.21x | 25.31x | 0.04% | 56.19B | |
| 20.62x | 6.35x | 13.89x | 1.54% | 54.83B | |
| -18.25x | 4.33x | -7.59x | -.--% | 23.04B | |
| -41x | 13.02x | -38.35x | -.--% | 22.7B | |
| 25.46x | 4.98x | 13.19x | -.--% | 20.23B | |
| 24.92x | 4.83x | 15.71x | -.--% | 17.83B | |
| -786.44x | 37.38x | -4208.26x | -.--% | 15.65B | |
| 45.88x | 18.59x | 47.88x | 0.08% | 15.24B | |
| 17.56x | 5.09x | 11.87x | -.--% | 14.03B | |
| Average | -68.94x | 312.84x | -413.93x | 0.17% | 25.02B | |
| Weighted average by Cap. | -35.50x | 135.75x | -253.50x | 0.35% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- SMMT Stock
- Valuation Summit Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
